Drug Trial Radar · NCT07778498
A Phase I/II, First-in-Human Study to Evaluate TJ102 in Participants With Advanced or Metastatic Ovarian Cancer and Other Solid Tumors.
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Sep 29, 2026
Primary completion
Sep 2029
Study completion Sep 2030
Sponsor
- Lead sponsor
- Phrontline BiopharmaIndustry
- Sponsor type
- Industry
- First posted
- Aug 21, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate whether TJ102, an investigational antibody-drug conjugate (ADC), can safely and effectively treat patients with advanced ovarian or other solid tumors. The main objectives of this study are : • To Determine the maximum tolerated dose (MTD) and recommended dose for expansion (RDE) of TJ102 • to show preliminary antitumor activity in patients with advanced ovarian or other solid tumors. Participants will: • Receive intravenous (IV) infusions of TJ102 at escalating dose levels (during dose escalation) or at the selected expansion dose. • Undergo regular tumor imaging to assess response. • Provide blood samples for pharmacokinetics (PK) and biomarker analysis. • Be monitored for side effects and overall tolerability. This study is being conducted in adult patients with advanced or metastatic ovarian or other solid tumors who have exhausted standard treatment options.
Conditions
- Ovarian Cancer
Interventions
TJ102Biological
TJ102 is a CDH6/FRa directed antibody conjugate with dual payloads
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with Dose-limiting toxicitiesTime frame: 2 years
- Number of participants with treatment-emergent adverse events (TEAEs)Time frame: 2 years
- Number of participants with treatment-related adverse events (TRAEs)Time frame: 2 years
Locations
9 sites in 2 countries. Site status is shown where the registry gives one.
South Texas Accelerated Research Therapeutics START LLC
Los Angeles, California · Recruiting
Florida Cancer Specialists Lake Nona
Orlando, Florida · Recruiting
START New York Long Island LLC
Lake Success, New York · Recruiting
Sidney Kimmel Cancer Center Jefferson Health
Philadelphia, Pennsylvania · Recruiting
SCRI Oncology Partners
Nashville, Tennessee · Recruiting
NEXT Houston
Houston, Texas · Recruiting
NEXT Dallas
Irving, Texas · Recruiting
NEXT Virginia
Fairfax, Virginia · Recruiting
FuDan Unversity Cancer Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.